Stock comparison
Harrow Health
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HROW
Harrow Health
Market cap
$1.23B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HROW | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 72B | LLY |
| Benjamin Graham | 73D | 86A | LLY |
| Philip Fisher | 65C | 86A | LLY |
| Peter Lynch | 75C | 74B | HROW |
| Joel Greenblatt | 47D | 78C | LLY |
| Charlie Munger | 55D | 85A | LLY |
| Terry Smith | 49D | 77C | LLY |
Side-by-side metrics
| Metric | HROW | LLY |
|---|---|---|
| Market cap | $1.23B | $1T |
| P/E (TTM) | - | 36.6x |
| EV/EBIT | 35.2x | 34.1x |
| ROIC (TTM) | 8.55% | 32.06% |
| Gross margin | 74.11% | 83.51% |
| Net margin | -5.57% | 34.98% |
| Revenue CAGR 5y | 39.22% | 23.17% |
| EPS CAGR 5y | - | 40.81% |
| Debt / Equity | 10.5x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HROW leads on
- P/E (TTM)-vs 36.6x+148%
- Revenue CAGR 5y39.22%vs 23.17%+41%
LLY leads on
- Net margin34.98%vs -5.57%+116%
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $1.23B+100%
- Debt / Equity1.4xvs 10.5x+87%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.